ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Corynoline promotes apoptosis and inhibits proliferation of glioblastoma via regulating the STAT3/Bcl-2 signalling pathway.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Corynoline is a bioactive compound extracted from Corydalis bungeana Turcz, which has shown significant potential in mitigating inflammatory responses and treating tumours. However, to the best of our knowledge, whether corynoline has anti-glioma activity has not been reported. In the present study, the activity of corynoline against glioblastoma (GBM) was evaluated, and its underlying mechanisms was explored. Corynoline was found to significantly inhibit the proliferation and promote the apoptosis of GBM cell lines U87 and LN229. Mechanistically, corynoline decreased the level of STAT3 phosphorylation, downregulated the expression of the anti-apoptotic protein Bcl2, and upregulated the expression of the pro-apoptotic proteins Bax, Bak, cleaved caspase-9, and cleaved caspase-3. Importantly, the STAT3 activator colivelin TFA markedly attenuated the effects of corynoline on GBM cells and inhibited the STAT3/Bcl2 signalling axis. Furthermore, corynoline treatment significantly inhibited the growth of GBM in vivo and was shown to modulate the STAT3/Bcl-2 signalling pathway. These results suggest that corynoline exerts antitumour activity against GBM by inhibiting the STAT3/Bcl2 pathway, indicating that corynoline might be a promising agent for the treatment of GBM.
Indexed as
Identifiers
41379317What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.